179 related articles for article (PubMed ID: 28945781)
21. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
22. Identification of therapy-sensitive and therapy-resistant neuroblastoma subtypes in stages III, IVs and IV.
Kyo Y; Tanaka T; Hayashi K; Iehara T; Kaneko M; Hosoi H; Sugimoto T; Hamasaki M; Kobayashi M; Sawada T
Cancer Lett; 2011 Jul; 306(1):27-33. PubMed ID: 21486686
[TBL] [Abstract][Full Text] [Related]
23. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
[TBL] [Abstract][Full Text] [Related]
24. Neuroblastoma: the association of anatomical tumour site, molecular biology and patient outcomes.
Salim A; Raitio A; Pizer B; Mullassery D; Losty PD
ANZ J Surg; 2021 May; 91(5):1000-1004. PubMed ID: 33506998
[TBL] [Abstract][Full Text] [Related]
25. The Detection of Genetic Parameters for Prognostic Stratification of Neuroblastoma Using Multiplex Ligation-Dependent Probe Amplification Technique.
Tumer S; Altungoz O; Bagci O; Olgun HN
Genet Test Mol Biomarkers; 2016 Feb; 20(2):74-80. PubMed ID: 26790040
[TBL] [Abstract][Full Text] [Related]
26. Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma.
Oldridge DA; Truong B; Russ D; DuBois SG; Vaksman Z; Mosse YP; Diskin SJ; Maris JM; Matthay KK
J Natl Cancer Inst; 2019 Nov; 111(11):1192-1201. PubMed ID: 30793172
[TBL] [Abstract][Full Text] [Related]
27. Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children's Cancer Group Neuroblastoma Committee (JCCG-JNBSG).
Ohira M; Nakamura Y; Takimoto T; Nakazawa A; Hishiki T; Matsumoto K; Shichino H; Iehara T; Nagase H; Fukushima T; Yoneda A; Tajiri T; Nakagawara A; Kamijo T
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053166
[TBL] [Abstract][Full Text] [Related]
28. Podoplanin lymphatic density and invasion correlate with adverse clinicopathologic and biological factors and survival in neuroblastomas.
Ramani P; Somerville MS; May MT
Am J Surg Pathol; 2012 Jun; 36(6):908-15. PubMed ID: 22588067
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.
Berbegall AP; Bogen D; Pötschger U; Beiske K; Bown N; Combaret V; Defferrari R; Jeison M; Mazzocco K; Varesio L; Vicha A; Ash S; Castel V; Coze C; Ladenstein R; Owens C; Papadakis V; Ruud E; Amann G; Sementa AR; Navarro S; Ambros PF; Noguera R; Ambros IM
Br J Cancer; 2018 May; 118(11):1502-1512. PubMed ID: 29755120
[TBL] [Abstract][Full Text] [Related]
30. Overall genomic pattern is a predictor of outcome in neuroblastoma.
Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
[TBL] [Abstract][Full Text] [Related]
31. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
32. Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without
Wieczorek A; Szewczyk K; Klekawka T; Stefanowicz J; Ussowicz M; Drabik G; Pawinska-Wasikowska K; Balwierz W
Front Oncol; 2023; 13():1134772. PubMed ID: 36865795
[TBL] [Abstract][Full Text] [Related]
33. Intratumour diversity of chromosome copy numbers in neuroblastoma mediated by on-going chromosome loss from a polyploid state.
Lundberg G; Jin Y; Sehic D; Øra I; Versteeg R; Gisselsson D
PLoS One; 2013; 8(3):e59268. PubMed ID: 23555645
[TBL] [Abstract][Full Text] [Related]
34. VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours.
Ramani P; Nash R; Radevsky L; Patel A; Luckett M; Rogers C
Histopathology; 2012 Dec; 61(6):1006-16. PubMed ID: 22804730
[TBL] [Abstract][Full Text] [Related]
35. Neuroblastoma arising from the organ of Zuckerkandl: an unusual site with a favorable biologic outcome.
Berdon WE; Stylianos S; Ruzal-Shapiro C; Hoffer F; Cohen M
Pediatr Radiol; 1999 Jul; 29(7):497-502. PubMed ID: 10398782
[TBL] [Abstract][Full Text] [Related]
36. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
[TBL] [Abstract][Full Text] [Related]
37. FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.
Ackermann S; Kocak H; Hero B; Ehemann V; Kahlert Y; Oberthuer A; Roels F; Theißen J; Odenthal M; Berthold F; Fischer M
BMC Cancer; 2014 Nov; 14():840. PubMed ID: 25406647
[TBL] [Abstract][Full Text] [Related]
38. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
Schleiermacher G; Michon J; Huon I; d'Enghien CD; Klijanienko J; Brisse H; Ribeiro A; Mosseri V; Rubie H; Munzer C; Thomas C; Valteau-Couanet D; Auvrignon A; Plantaz D; Delattre O; Couturier J;
Br J Cancer; 2007 Jul; 97(2):238-46. PubMed ID: 17579628
[TBL] [Abstract][Full Text] [Related]
39. Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.
Coco S; Theissen J; Scaruffi P; Stigliani S; Moretti S; Oberthuer A; Valdora F; Fischer M; Gallo F; Hero B; Bonassi S; Berthold F; Tonini GP
Int J Cancer; 2012 Oct; 131(7):1591-600. PubMed ID: 22234802
[TBL] [Abstract][Full Text] [Related]
40. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
